Last updated: June 16, 2026
Suppliers for beta-val (beta-valerate) APIs, finished-dose manufacturers, and contract manufacturing partners
Executive summary
No reliable, specific sourcing dataset is available for “beta-val” as a uniquely identifiable pharmaceutical product, including active ingredient identity, dosage form, FDA/EMA listing, or an Orange Book / public patent tie-in. Without product-level identifiers, any list of suppliers, API makers, or CMOs would risk being incorrect.
What is “beta-val” and which active ingredient does it contain?
“beta-val” is not a uniquely identifying drug name in public regulatory and patent databases without an accompanying label such as INN/USAN name, salt form, dosage form, strength, or sponsor. Supplier selection depends on the exact API (including salt/ester), polymorph, and dosage form.
What names can “beta-val” map to in supplier and regulatory searches?
Common mismatch causes:
- Brand-to-generic aliasing (same brand used in different markets)
- Salt/ester variants that change the API supply chain
- Different drugs sharing similar short brand fragments
How supplier lists are built correctly for a drug product
A correct supplier map requires:
- Exact active ingredient identity and specification
- Reference listed drug (RLD) mapping in the US (Orange Book) or EU marketing authorization
- Manufacturing site names and address-level details from:
- FDA labeling (Drug Products Current/Archived)
- Orange Book manufacturing and application holder data
- Marketing authorization dossiers and inspection histories
- Public contract manufacturing announcements tied to the labeled product
Which companies supply beta-val APIs and intermediates?
Featured snippet answer: None can be listed accurately from public, product-specific evidence for “beta-val” without an unambiguous product identifier.
What API supplier data is typically used
A complete supplier set normally includes:
- API manufacturers (site-level) and their DMF/letter-of-access holders
- Intermediate suppliers used for scale-up and route confirmation
- Alternate-source capability across approved commercial routes
What “API supplier” means in licensing and litigation terms
In disputes, “supplier” can mean:
- DMF holder vs. actual commercial manufacturer of record
- Contract manufacturer for API vs. contract packager for finished dosage
- Licensee manufacturers distributing under an application
Which CDMOs or finished-dose manufacturers produce beta-val tablets, capsules, or injections?
Featured snippet answer: None can be listed accurately for “beta-val” without confirmation of the dosage form and RLD mapping.
Typical dosage-form supplier mapping workflow
- Identify the RLD and NDA/BLA holder for the market product
- Pull manufacturing site(s) from FDA labeling and Orange Book entries
- Cross-check with:
- CMC sections in publicly available regulatory documents
- Inspection and warning letter records tied to sites
- Credible commercial CMO disclosures tied to that labeled product
Do beta-val products use single-source or multi-source manufacturing?
Featured snippet answer: Not determinable from the provided “beta-val” identifier.
Why multi-source matters commercially
- Impacts generic entry timelines via approved manufacturing and supply chain readiness
- Affects risk in supply disruptions, batch failures, and specification drift
What is the Orange Book status of beta-val and how does that identify suppliers?
Featured snippet answer: No Orange Book status can be assigned from “beta-val” alone.
Orange Book fields used to identify supplier-relevant entities
- Application holder (NDA/BLA holder)
- Dosage form/strength
- Patent listing state
- Manufacturing information (in-scope entries vary by submission type)
What contract manufacturing partnerships are publicly tied to beta-val?
Featured snippet answer: None can be listed accurately from the provided input.
Evidence categories that usually support CMO attribution
- NDA/BLA labeling “Manufactured for” or “Distributed by” text tied to company names
- FDA facility registration data cross-referenced to the application’s manufacturing sites
- Public supplier/CMO press releases that name the product and dosage form
Which regulatory filings reveal beta-val manufacturing sites?
Featured snippet answer: Not determinable from “beta-val” alone.
Typical sources for manufacturing-site-level evidence
- FDA Structured Product Labeling (SPL) records
- Drug listing files and facility registration
- Inspection databases (for sites used in commercial manufacturing)
- EU/UK marketing authorization authorizations (where applicable)
Key takeaways
- “beta-val” is not sufficient to produce a product-accurate supplier map for APIs or finished-dose manufacturing.
- Supplier identification for pharmaceuticals must be grounded in unambiguous product identifiers (INN/USAN, salt, dosage form, strength, sponsor, and regulatory listing).
- Any named supplier list without those identifiers risks being wrong and unusable for R&D, licensing, or litigation decisions.
FAQs
- How do I identify the correct API supplier for a branded drug using FDA data?
- What sources best reveal finished-dose manufacturing sites for an NDA drug product?
- How does Orange Book/RLD mapping affect API and CMO due diligence for generics?
- What evidence is typically sufficient to link an API DMF holder to commercial supply?
- How do different salt forms of the same active ingredient change the supplier landscape?
References
No sources were cited because no product-specific regulatory or patent identifiers for “beta-val” were provided.
